| Literature DB >> 34649056 |
Alireza Mafi1, Negar Yadegar2, Marziyeh Salami3, Raziyeh Salami4, Omid Vakili5, Esmat Aghadavod6.
Abstract
Diabetic nephropathy (DN), also known as diabetic kidney disease (DKD), is a drastic renal complication of type 1 and type 2 diabetes mellitus (DM). Poorly controlled DM over the years, may disrupt kidneys' blood vessels, leading to the hypertension (HTN) and DN onset. During DN, kidneys' waste filtering ability becomes disturbed. Being on a healthy lifestyle and controlling both DM and HTN are now the best proceedings to prevent or at least delay DN occurrence. Unfortunately, about one-fourth of diabetic individuals eventually experience the corresponding renal failure, and thus it is critical to discover effective diagnostic biomarkers and therapeutic strategies to combat DN. In the past few years, circular RNAs (circRNAs), as covalently closed endogenous non-coding RNAs (ncRNAs), are believed to affect DN pathogenesis in a positive manner. CircRNAs are able to impact different cellular processes and signaling pathways by targeting biological molecules or various molecular mechanisms. Still, as a key regulatory axis, circRNAs can select miRNAs as their molecular targets, in which they are considered as miRNA sponges. In this way, circRNA-induced suppression of particular miRNAs may prevent from DN progression or promotes the DN elimination. Since the expression of circRNAs has also been reported to be increased in DN-associated cells and tissues, they can be employed as either diagnostic biomarkers or therapeutic targets.Entities:
Keywords: Biomarker; Circular RNAs; Diabetic nephropathy; MicroRNAs; Treatment
Mesh:
Substances:
Year: 2021 PMID: 34649056 DOI: 10.1016/j.prp.2021.153618
Source DB: PubMed Journal: Pathol Res Pract ISSN: 0344-0338 Impact factor: 3.250